Press Releases Better Therapeutics, Inc.

Equities

BTTX

US08773T1043

Market Closed - OTC Markets Other stock markets 03:27:10 2024-05-22 pm EDT			5-day change	1st Jan Change
0.01 ^USD	-9.09%		-9.09%	-94.87%

Mar. 21	Better Therapeutics, Inc. Receives Notice of Default from Hercules Capital, Inc	CI
Mar. 20	Better Therapeutics, Inc.(NasdaqCM:BTTX) dropped from S&P TMI Index	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq	Mar. 14	BU
Better Therapeutics : Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq - Form 8-K	Mar. 14	PU
Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers	Mar. 05	BU
Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)	Mar. 04	BU
Transcript: Better Therapeutics CEO Interview with RedChip - Form 8-K	Mar. 04	PU
Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease	Feb. 20	BU
Better Therapeutics Signs Rebate Agreement with One of the Largest Pharmacy Benefit Managers in the US for its AspyreRx Diabetes Treatment	Feb. 06	BU
Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone	Jan. 17	BU
Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States	Jan. 03	BU
Better Therapeutics Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease	Jan. 02	BU
Better Therapeutics : Failure to Satisfy Listing Rule - Form 8-K	Dec. 18	PU
Better Therapeutics Strengthens Financial Position Through Amendment to Debt Facility and Implementation of Cost Reductions	Nov. 28	BU
Frost & Sullivan Honors Better Therapeutics with the 2023 Technology Innovation Leadership Award	Nov. 14	BU
Better Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates	Nov. 09	BU
Better Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 09, 2023	Nov. 08	BU
Better Therapeutics : Results of Operations and Financial Condition - Form 8-K	23-10-30	PU
Better Therapeutics to participate in the American College of Lifestyle Medicine's 2023 Annual Conference	23-10-27	AQ
Better Therapeutics to Participate in the American College of Lifestyle Medicine’s 2023 Annual Conference	23-10-26	BU
Better Therapeutics Announces Launch of AspyreRxTM to Treat Adults with Type 2 Diabetes	23-10-16	BU
Better Therapeutics Announces New Data Highlighting Concurrent Use of AspyreRx and GLP-1 Receptor Agonists to Treat Type 2 Diabetes	23-10-11	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Better Therapeutics, Inc.

Equities

BTTX

US08773T1043

Press Releases

Filters